Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efimosfermin Alfa in MASH (ZENITH-2)
NCT07221188Phase 3Recruiting
- Sponsor
- GSK
- Start
- Dec 2025
- Primary completion
- Mar 2028
- Modality
- Fc-Fusion Proteins
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of efimosfermin in metabolic dysfunction-associated steatohepatitis (MASH) (3 arms), sponsored by GSK. Primary endpoints: Treatment-Emergent Adverse Events at 52 weeks, Treatment-Emergent Adverse Events leading to discontinuation at 52 weeks and 1 more. Started Dec 2025; status: recruiting.
02
Drugs
efimosfermin
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NCT07221188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07221188.